Treatment of venous thromboembolism in cancer patients

Cancer Control

Volumn 12, Issue SUPPL. 1, 2005, Pages 17-21

  Lee, Agnes ^a   Levine, Mark ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; WARFARIN;

BLEEDING; CANCER PATIENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; REVIEW; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 25144514872     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/1073274805012003s04     Document Type: Review

References (26)

1. Silverstein M, Heit J, Mohr D, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
2. Heit J, Silverstein M, Mohr D, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.
3. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-722.
4. Hutten B, Prins M, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078-3083.
5. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
6. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850.
7. Baron JA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer. Lancet. 1998;351:1077-1080.
8. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood. 1983;62:14-31.
9. Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: insights and innovations in thrombosis and cancer. J Thromb Haemost. 2003;1: 1456-1463.
10. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):401S-428S.
11. van Dongen CJJ, van den Belt AGM, Prins MH, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. The Cochrane Database of Systematic Reviews. 2004, Issue 4.
12. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337: 688-698.
13. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
14. Lee AYY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol. 2004;128:291-302.
15. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
16. Koopman M, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
17. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;334:657-662.
18. Merli G, Spiro T, Olsson C, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001;134:191-202.
19. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):204S-233S.
20. Lee A, Levine M, Baker R, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
21. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729-1735.
22. Das SK, Cohen AT, Edmondson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg. 1996;20:521-526.
23. Lee AYY, Rickles FR, Julian JA, et al. Randomized comparison low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123-2129.
24. Klerk CP, Smorenburg SM, Often HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130-2135.
25. Nightingale SL. From the Food and Drug Administration. JAMA. 1993; 270:1672.
26. Noble SIR, Finlay IG. Is long-term LMWH acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med. 2005;19:1-5.